World's Best Scientists 2026 revealed!
Lung Cancer
H-index 42

Lung Cancer

0169-5002

Published by: Elsevier

https://www.journals.elsevier.com/lung-cancer

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 337 409 711 41

Additional Metrics

Number of Best Scientists*: 633
Documents by Best Scientists*: 875
Top 100 Ranked Scientists*: 10
SCIMAGO H-index: 154
SCIMAGO SJR: 1.752
Impact Factor: 4.4

Overview

Top Research Topics at Lung Cancer?

Lung Cancer was organized to reinforce research efforts on Internal medicine, Lung cancer, Oncology, Non small cell and Surgery. It tackles research in Chemotherapy, non-small cell lung cancer (NSCLC) and Radiation therapy as part of the general discipline of Internal medicine, however, it also discusses concepts in In patient. In particular, the Chemotherapy works presented emphasize discussions on Phases of clinical research.

The research on Lung cancer featured in it combines topics in other fields like Cancer, Cancer research, Respiratory disease and Radiology. The work on Cancer research addressed in it expands to the thematically related Epidermal growth factor receptor. The journal explores issues in Oncology which can be linked to other research areas like Carboplatin, Cisplatin, Carcinoma, Lung and Gemcitabine.

In the Surgery research discussed, Survival rate, Regimen, Performance status, Stage (cooking) and Neutropenia are all tackled. The study on Pathology presented in the journal intersects with the topics under Adenocarcinoma.

  • Internal medicine (52.88%)
  • Lung cancer (48.23%)
  • Oncology (44.53%)

What are the most cited papers published in the journal?

  • Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials (2517 citations)
  • Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument * (586 citations)
  • Tobacco smoking and cancer: a brief review of recent epidemiological evidence. (474 citations)

Research areas of the most cited articles at Lung Cancer:

The published papers mainly tackle studies in Lung cancer, Internal medicine, Oncology, Pathology and Cancer. The most cited papers facilitate discussions on Lung cancer that incorporate concepts from other fields like Respiratory disease, Cancer research, Surgery, Carcinoma and Adenocarcinoma. Most of the works presented in the most cited papers deal with Internal medicine but they intersect with the subject of Gastroenterology.

What topics the last edition of the journal is best known for?

  • Internal medicine
  • Cancer
  • Gene

The previous edition focused in particular on these issues:

Lung cancer, Internal medicine, Oncology, Cancer research and Lung are the subjects of interest in the journal. The journal deals with Lung cancer in conjunction with 2019-20 coronavirus outbreak and similar fields in Intensive care medicine. Most of the Internal medicine studies addressed also intersect with Gastroenterology.

Issues in Oncology were discussed, taking into consideration concepts from other disciplines like Adverse effect, Proportional hazards model, Epidermal growth factor receptor and Carcinoma. While Lung Cancer focused on Cancer research, it was also able to explore topics like Mutation, KRAS and Immunohistochemistry. The Lung study featured in the journal draws parallels with the field of Adenocarcinoma.

The most cited articles from the last journal are:

  • Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study (11 citations)
  • The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. (10 citations)
  • Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). (9 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Lung Cancer (based on the number of publications) are:

  • Kenneth J. O'Byrne (149 papers) published 4 papers at the last edition,
  • Corinne Faivre-Finn (137 papers) published 6 papers at the last edition, 4 less than at the previous edition,
  • Rafael Rosell (128 papers) published 2 papers at the last edition, 1 more than at the previous edition,
  • Sanjay Popat (92 papers) published 9 papers at the last edition, 1 less than at the previous edition,
  • Jean-Paul Sculier (84 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Lung Cancer (based on the number of publications) are:

  • University of Texas MD Anderson Cancer Center (123 papers) published 7 papers at the last edition the same number as at the previous edition,
  • Harvard University (111 papers) published 8 papers at the last edition, 1 more than at the previous edition,
  • Netherlands Cancer Institute (102 papers) published 10 papers at the last edition, 3 more than at the previous edition,
  • Okayama University (85 papers) published 1 paper at the last edition, 6 less than at the previous edition,
  • University of Turin (83 papers) published 4 papers at the last edition, 4 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 42.12% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 15.86% were posted by at least one author from the top 10 institutions publishing in the journal. Another 13.79% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 14.14% of all publications and 56.21% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Exploring Career Opportunities in Oncology

An increasing interest in Oncology and the battle against Lung Cancer may lead numerous researchers and scientists to consider a career in the healthcare field, perhaps as a nurse practitioner. Nurse practitioners play a crucial role in patient care, assisting with chemotherapy treatments, radiation therapies, and patient counseling, especially in Rhode Island where nurse practitioners can practice independently.

One must fulfill certain educational, certification, and training requirements to pursue this profession. Detailed information about these requirements can be obtained from trusted and authoritative sources. For those who wish to seize the opportunity to be at the forefront of lung cancer treatment and research in Rhode Island, explore the nurse practitioner program requirements Rhode Island, which outlines the necessary credentials and practical experience needed to secure a successful career in Oncology. It includes information alluding to patient procedures, chemotherapy, and radiation methods prevalent in combating lung cancer, and other related disorders. By pursuing the nurse practitioner track, one can substantially contribute to clinical research and directly influence patient outcomes.

This profession yields the unique opportunity to not only impact the medical world indirectly via research but also influence it directly via patient care. Therefore, explore, research, and dive into the world of Oncology to make a difference in the lives of those battling lung cancer.

Top Publications

  • The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.

    Keith M. Kerr;Frédéric Bibeau;Erik Thunnissen;Johan Botling

    (2021)
    150 Citations
  • ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.

    Filippo G. Dall’Olio;Ilaria Maggio;Maria Massucci;Veronica Mollica

    (2020)
    145 Citations
  • Lung cancer prediction by Deep Learning to identify benign lung nodules.

    Marjolein A Heuvelmans;Peter M A van Ooijen;Sarim Ather;Carlos Francisco Silva

    (2021)
    127 Citations
  • Mechanisms of osimertinib resistance and emerging treatment options.

    Sabine Schmid;Janice J.N. Li;Natasha B. Leighl

    (2020)
    126 Citations
  • Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

    Kazuhiko Nakagawa;Toyoaki Hida;Hiroshi Nokihara;Masahiro Morise

    (2020)
    113 Citations
  • Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.

    Jeffrey C. Thompson;Wei-Ting Hwang;Christiana Davis;Charuhas Deshpande

    (2020)
    108 Citations
  • Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer

    Hyun Ae Jung;Jae Myoung Noh;Jong-Mu Sun;Se-Hoon Lee

    (2020)
    106 Citations
  • Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.

    (2022)
    104 Citations
  • Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

    David E. Gerber;D. Ross Camidge;Daniel Morgensztern;Jeremey Cetnar

    (2020)
    98 Citations
  • Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

    N. Yamamoto;T. Seto;M. Nishio;K. Goto

    (2021)
    86 Citations

Related Online Degrees & Career Pathways

For those interested in healthcare but not yet ready to commit to medical school, there are several accessible online degree options to explore. Many students start with a Bachelor of Science in Nursing, and finding the cheapest online BSN programs can make this path more affordable and flexible.

Registered Nurses looking to advance their careers often pursue RN to BSN programs. Understanding the cost of RN to BSN programs is crucial as it impacts long-term career growth and earning potential.

For those seeking leadership and clinical expertise, Doctor of Nursing Practice (DNP) degrees offer a practical route. There are many well-regarded DNP programs available online that combine affordability with quality education.

Finally, certain nursing programs simplify admissions by not requiring standardized tests such as TEAS or HESI. Prospective students looking for more accessible entry points can find optimal choices among the nursing programs no TEAS requirement.

Best Scientists Contributing to This Journal

Recently Published Articles